<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="life-11-00214-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">life-11-00214-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>The main characteristics of included studies.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year and Country</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Period</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Sample</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comparator Group</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Measures</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elms et al. [
     <xref rid="B47-life-11-00214" ref-type="bibr">47</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019, US (Colorado)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study
     <break/>Grade: *
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 11 (8 F, 3 M);
     <break/>mean age 39.91 ± 17.39;
     <break/>DSM-5 diagnosis of PTSD
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 1: 9 mg/d (mean dose, range 1–16) CBD liquid oil spray; 
     <break/>N = 4: 25 mg/d (mean dose, range 25–100) CBD capsule; 
     <break/>N = 6: both formulations
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in PCL-5 score</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decline in PCL-5 mean scores of 21% (from 51.82 to 40.73) in 91% subjects at 4 weeks. Further decrease of 9% (to 37.14) in 75% subjects at 8 weeks.</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabinak et al. [
     <xref rid="B52-life-11-00214" ref-type="bibr">52</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019, US (Michigan)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute study</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized, double-blind, placebo-controlled, between-subjects study
     <break/>Grade: ****
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 71 (36 F, 35 M)
     <break/>age 20–45; 
     <break/>N = 22: DSM-5 diagnosis of PTSD; N = 24: TEC; N = 25: HC
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THC 7.5 mg capsule </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Threat-processing paradigm at fMRI (amygdala, mPFC/rACC activation and functional connectivity)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In the PTSD group THC lowered threat-related bilateral amygdala activity (drug x group interaction left: F(1,65): 5.131, 
     <italic>p</italic> = 0.027; right: F(1,65) = 4.456, 
     <italic>p</italic> = 0.039), increased mPFC activation (drug x group interaction F(2,65) = 4.887, 
     <italic>p</italic> = 0.011), increased mPFC-right amygdala functional coupling (F(1,65) = 8.181, 
     <italic>p</italic> = 0.006).
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith et al. [
     <xref rid="B48-life-11-00214" ref-type="bibr">48</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017, Canada</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 years, variable treatment duration and time to follow-up</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study
     <break/>Grade: ***
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 100 veterans 
     <break/>(3 F, 97 M);
     <break/>mean age 43;
     <break/>DSM-5 diagnosis of PTSD
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medical cannabis (THC and CBD at variable percentages), start dose 1 g/d, self-titrated based on clinical response, maximum dose 10 g/d</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in PTSD-related symptoms, pain, and social impact, scored 1–10 as reported in clinical charts</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decrease of PTSD aggregate symptoms score from 7 to 2.9 (59% reduction, ES 1.5, 
     <italic>p</italic> &lt; 0.0001), decrease of suicidal thoughts score from 4.1 to 0.9 (77% reduction, ES 1, 
     <italic>p</italic> &lt; 0.0001), decrease of pain score from 6.6 to 3.4 (48% reduction, ES 1.5), decrease of PTSD social impact score from 6.6 to 2.7 (59% reduction, ES 1.2, 
     <italic>p</italic> &lt; 0.0001) after treatment.
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cameron et al. [
     <xref rid="B40-life-11-00214" ref-type="bibr">40</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014, Canada</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 months</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study
     <break/>Grade: **
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 104 males; 
     <break/>mean age 32.7 (range 19–55);
     <break/>91% of which affected by DSM-IV-TR PTSD
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabilone, mean initial dose 1.4 mg/d (range 0.5–2), mean final dose 4 mg/d (range 0.5–6), mean length of treatment 11.2 weeks (range 1 day–36 weeks)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in PCL-C scores</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant reduction of PLC-C scores (54.7 ± 13 vs 38.8 ± 7.1, 
     <italic>p</italic> = 0.001) after treatment, consistent with a reduction from moderate to mild-borderline symptoms.
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Greer et al. [
     <xref rid="B49-life-11-00214" ref-type="bibr">49</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014, US (California)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 months</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study
     <break/>Grade: **
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 80 adults; 
     <break/>DSM-IV diagnosis of PTSD
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medical cannabis (THC and CBD at variable percentages), start dose 1 g/d, self-titrated based on clinical response, maximum dose 10 g/d</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in CAPS scores</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decrease in total CAPS score (22.5 ± 16.9 vs 98.8 ± 17.6, 
     <italic>p</italic> &lt; 0.0001) in subjects using cannabis. Significant reductions in CAPS symptom cluster scores (Cannabis × Cluster: F(2,158) = 39.87, 
     <italic>p</italic> &lt; 0.0001). 
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jetly et al. [
     <xref rid="B39-life-11-00214" ref-type="bibr">39</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014, Canada</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two periods of 7 weeks separated by a period of 2 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized, double-blind, placebo-controlled crossover study
     <break/>Grade: ****
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 10 military male personnel; 
     <break/>age 18–65;
     <break/>DSM-IV-TR diagnosis of PTSD, current distressing nightmares, and difficulty falling/staying asleep as evaluated by CAPS
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabilone 0.5 mg (start dose) weekly titrated to a maximum of 3 mg</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in CAPS Recurrent Distressing Dreams and Difficulty Falling or Staying Asleep items, CGI-C, PTSD Dream Rating Scale, WBQ scores, Sleep Diary</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant reduction of CAPS Recurring and Distressing Dream Frequency (−1.9 ± 1.3 vs −0.4 ± 1.4, 
     <italic>p</italic> = 0.05) and Intensity (−1.7 ± 1.3 vs −0.6 ± 1.1, 
     <italic>p</italic> = 0.06) scores, significant lower CGI-C (1.9 ± 1.1 vs 3.2 ± 1.2, 
     <italic>p</italic> = 0.05) score, significant increase of WBQ (49.3 ± 21.6 vs 23 ± 17.2, 
     <italic>p</italic> = 0.04) score after treatment with nabilone.
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roitman et al. [
     <xref rid="B37-life-11-00214" ref-type="bibr">37</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014, Israel</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 weeks</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-randomized, open-label, adjusted doses, study
     <break/>Grade: ***
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 10 (3 F, 7 M); 
     <break/>mean age 52.3 ± 8.3; 
     <break/>DSM-IV PTSD diagnosis
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCH oil 0.1 cc (=2.5 mg) bid, after 2 days raised to 0.2 cc (=5 mg) bid</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in CAPS, CGI, PSQI, NFQ, NES scores</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant decrease in CAPS arousal (32.3 ± 4.73 vs 24.3 ± 9.11, 
     <italic>p</italic> &lt; 0.02), CGI-S (6 ± 0.47 vs 4.9 ± 0.99, 
     <italic>p</italic> &lt; 0.02), NFQ frequency of nightmares (0.81 ± 0.55 vs 0.44 ± 0.41, 
     <italic>p</italic> &lt; 0.04), NES (32.2 ± 11.29 vs 22.9 ± 8.7, 
     <italic>p</italic> &lt; 0.002), PSQI (17.20 ± 2.65 vs 13.9 ± 4.48, 
     <italic>p</italic> &lt; 0.05) scores after treatment with THC.
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bonn-Miller et al. [
     <xref rid="B50-life-11-00214" ref-type="bibr">50</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013, US (California)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional study
     <break/>Grade: **
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 217 (26.7% F, 73.3% M); 
     <break/>mean age 41.2 ± 14.9 (range 18–74 years);
     <break/>40 (18.9%) affected by PTSD
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medical cannabis, flexible-dose (mean use: 3 times/d, 9–12 g/week)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subjective help received from medical cannabis as measured by a 5-point-likert scale</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Traumatic intrusions predicted cannabis helpfulness (beta 0.22, 
     <italic>p</italic> &lt; 0.01), as well as the use of cannabis for social anxiety problems (
     <italic>p</italic> &lt; 0.004).
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reznik [
     <xref rid="B51-life-11-00214" ref-type="bibr">51</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012, Israel</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 years</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naturalistic observational study
     <break/>Grade: **
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 167
     <break/>25 pure PTSD, 
     <break/>43 PTSD + clinical depression, 
     <break/>88 PTSD + chronic pain
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicinal cannabis (20–25% THC), range 2–3 g/d</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in CAPS, QOLS, CGI-I scores</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant improvement in QOLS and pain scores in most cases, with some positive changes in CAPS scores. The majority of improved subjects belonged to comorbidity groups.</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fraser [
     <xref rid="B38-life-11-00214" ref-type="bibr">38</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009, Canada</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 years of clinical observation; flexible duration of treatment with nabilone (depending on the clinical response) </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-randomized, open-label study
     <break/>Grade: ***
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N = 47 (27 F, 20 M);
     <break/>mean age 44 ± 9; 
     <break/>DSM-IV-TR diagnosis of PTSD, treatment-resistant nightmares
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabilone 0.5 mg (start dose) before bedtime, then titrated; doses were kept below 6 mg/d</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Changes in the intensity of PTSD-related nightmares </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (72%) subjects experienced total cessation or significant reduction of nightmares. Nabilone discontinuation was successful in 4 (8%) subjects, whilst the others experienced a recurrence of nightmares.</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <bold>Note:</bold> CAPS: Clinician-Administered PTSD Scale; CBD: Cannabidiol; CGI: Clinical Global Impressions; CGI-C: Clinical Global Impressions—Change; CGI-I: Clinical Global Impressions—Improvement; CGI-S: Clinical Global Impressions—Severity; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; ES: Effect Size; fMRI: Functional Magnetic Resonance Imaging; HC: Healthy Control; mPFC: Medial Pre-Frontal Cortex; NES: Nightmare Effects Survey; NFQ: Nightmare Frequency Questionnaire; PCL-C: Post-Traumatic Checklist—Civilian Version; PCL-5: PTSD Checklist for the DSM-5; PSQI: Pittsburgh Sleep Quality Index; PTSD: Post-Traumatic Stress Disorder; QOLS: Quality of Life Scale; rACC: Rostral Adjacent Cingulate Cortex; TCH: delta-9-tetrahydrocannabinol; TEC: Trauma-Exposed-Control; WBQ: Well Being Questionnaire. GRADE: * very low; ** low; *** moderate; **** high.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
